Teva presents new data on SC olanzapine

The US subsidiary of Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia.

Olanzapine is the active ingredient of Zyprexa Relprevv, developed by Eli Lilly (NYSE: LLY), but which has historically struggled in the long-acting injectable market because of post-injection delirium/sedation syndrome (PDSS) risk associated with the product.

In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.